A phase 2 study of pembrolizumab and weekly paclitaxel for platinum-resistant epithelial ovarian cancer

This publication has 30 references indexed in Scilit:

• Chemotherapy With Or Without Pembrolizumab Followed By Maintenance With Olaparib Or Placebo For First-Line Treatment Of Advanced BRCA Non-Mutated Epithelial Ovarian Cancer: Results From The Randomized Phase 3 ENGOT-OV43/GOG-3036/KEYLYNK-001 Study
  International Journal of Gynecological Cancer, 2025
• Immunotherapy in Ovarian Cancer
  Archivum Immunologiae et Therapiae Experimentalis, 2022
• Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers
  Gynecologic Oncology, 2019
• Phase II trial of pembrolizumab with cisplatin and gemcitabine in women with recurrent platinum-resistant ovarian cancer
  Gynecologic Oncology, 2019
• Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer
  JAMA Oncology, 2019
• PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer
  Gynecologic Oncology, 2016
• Low dose cyclophosphamide: Mechanisms of T cell modulation
  Cancer Treatment Reviews, 2016
• Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
  The Lancet Oncology, 2015
• Paclitaxel and immune system
  European Journal of Pharmaceutical Sciences, 2009
• The role of MyD88 and TLR4 in the LPS-mimetic activity of Taxol
  European Journal of Immunology, 2001